Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity.
Immune stimulation has emerged as a promising approach to the treatment of neoplastic diseases. Currently approved therapeutics, such as anti-CTLA4 and anti-PD1, are primarily aimed at blocking inhibitory signaling by immune cells. An alternative and potentially synergistic approach would involve activation of immune pathways by agonism of stimulatory receptors, such as CD40. Agonistic antibodies, while promising in principle, have encountered significant barriers in clinical trials limited by the systemic toxicity of such approaches. Using a mouse model humanized for both Fc receptors and CD40, we previously demonstrated enhanced antitumor activity with an Fc-modified antibody. We now demonstrate that this model recapitulates the platelet and hepatic toxicities seen with anti-CD40 antibodies in patients, providing a predictive measure of the dose-limiting activity of this approach. We further show that such toxicity can be circumvented and durable systemic antitumor immunity achieved by intratumoral delivery of an Fc-engineered anti-CD40 agonistic antibody.
['Knorr|David A|DA|', 'Dahan|Rony|R|', 'Ravetch|Jeffrey V|JV|0000-0003-2024-9041']
D000818:Animals D000911:Antibodies, Monoclonal D019013:CD40 Antigens D060908:CTLA-4 Antigen D045744:Cell Line, Tumor D006801:Humans D007141:Immunoglobulin Fc Fragments D007167:Immunotherapy D015552:Injections, Intralesional D051379:Mice
CD40 agonist antibody Fc receptor immunotherapy